Laskin OL - Search Results

1

Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men.

Depré M, Meeter C, Van Hecken A, Laskin OL, Buntinx A, De Schepper PJ. Depré M, et al. Among authors: laskin ol. Clin Pharmacol Ther. 1992 Oct;52(4):409-12. doi: 10.1038/clpt.1992.163. Clin Pharmacol Ther. 1992. PMID: 1424413 Clinical Trial.

2

Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations.

Schwartz JI, Laskin OL, Meeter CA, Patterson PM, Schneider SH, Lasseter KC, Seibold JR. Schwartz JI, et al. Among authors: laskin ol. Clin Pharmacol Ther. 1994 Jan;55(1):50-4. doi: 10.1038/clpt.1994.9. Clin Pharmacol Ther. 1994. PMID: 8299317 Clinical Trial.

3

Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor.

Van Hecken A, Depre M, De Lepeleire I, Laskin O, Au T, Woolf E, Yeh KC, De Schepper PJ. Van Hecken A, et al. Int J Clin Pharmacol Res. 1994;14(2):45-50. Int J Clin Pharmacol Res. 1994. PMID: 7530697 Clinical Trial.

4

Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trial.

Laskin OL, Patterson PM, Shingo S, Lasseter KC, Shamblen EC. Laskin OL, et al. J Clin Pharmacol. 1993 Jul;33(7):636-9. doi: 10.1002/j.1552-4604.1993.tb04716.x. J Clin Pharmacol. 1993. PMID: 8366188 Clinical Trial.

5

Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome.

Roberts RB, Laskin OL, Laurence J, Scavuzzo D, Murray HW, Kim YT, Connor JD. Roberts RB, et al. Among authors: laskin ol. Clin Pharmacol Ther. 1987 Oct;42(4):365-73. doi: 10.1038/clpt.1987.165. Clin Pharmacol Ther. 1987. PMID: 2444379 Clinical Trial.

6

Netilmicin and gentamicin multidose kinetics in normal subjects.

Laskin OL, Longstreth JA, Smith CR, Lietman PS. Laskin OL, et al. Clin Pharmacol Ther. 1983 Nov;34(5):644-50. doi: 10.1038/clpt.1983.227. Clin Pharmacol Ther. 1983. PMID: 6627825 Clinical Trial.

7

Distribution of lenalidomide into semen of healthy men after multiple oral doses.

Chen N, Lau H, Choudhury S, Wang X, Assaf M, Laskin OL. Chen N, et al. Among authors: laskin ol. J Clin Pharmacol. 2010 Jul;50(7):767-74. doi: 10.1177/0091270009355157. Epub 2010 Feb 16. J Clin Pharmacol. 2010. PMID: 20160158 Clinical Trial.

8

Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, Roberts RB. Laskin OL, et al. Clin Pharmacol Ther. 1987 May;41(5):546-55. doi: 10.1038/clpt.1987.70. Clin Pharmacol Ther. 1987. PMID: 3568539

9

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL. Chen N, et al. Among authors: laskin ol. J Clin Pharmacol. 2007 Dec;47(12):1466-75. doi: 10.1177/0091270007309563. Epub 2007 Oct 22. J Clin Pharmacol. 2007. PMID: 17954615 Clinical Trial.

10

Acyclovir kinetics in end-stage renal disease.

Laskin OL, Longstreth JA, Whelton A, Rocco L, Lietman PS, Krasny HC, Keeney RE. Laskin OL, et al. Clin Pharmacol Ther. 1982 May;31(5):594-601. doi: 10.1038/clpt.1982.83. Clin Pharmacol Ther. 1982. PMID: 7075109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters